PURPOSE: The precise molecular targets of IFN-alpha therapy in the context of malignant melanoma are unknown but seem to involve signal transducers and activators of transcription 1 signal transduction within host immune effector cells. We hypothesized that the in vitro transcriptional response of patient peripheral blood mononuclear cells (PBMC) to IFN-alpha would be similar to the in vivo response to treatment with high-dose IFN-alpha. EXPERIMENTAL DESIGN: The gene expression profiles of PBMCs and immune cell subsets treated in vitro with IFN-alpha were evaluated, as were PBMCs obtained from melanoma patients receiving adjuvant IFN-alpha. RESULTS: Twenty-seven genes were up-regulated in PBMCs from normal donors after treatment with IFN-alpha in vitro for 18 hours (>2-fold, P < 0.001). A subset of these genes (in addition to others) was significantly expressed in IFN-alpha-treated T cells, natural killer cells, and monocytes. Analysis of gene expression within PBMCs from melanoma patients (n = 13) receiving high-dose IFN-alpha-2b (20 MU/m(2) i.v.) revealed significant up-regulation (>2-fold) of 21 genes (P < 0.001). Also, the gene expression profile of in vitro IFN-alpha-stimulated patient PBMCs was similar to that of PBMCs obtained from the same patient after IFN-alpha therapy. CONCLUSIONS: This report is the first to describe the transcriptional response of T cells, natural killer cells, and monocytes to IFN-alpha and characterize the transcriptional profiles of PBMCs from melanoma patients undergoing IFN-alpha immunotherapy. In addition, it was determined that microarray analysis of patient PBMCs after in vitro stimulation with IFN-alpha may be a useful predictor of the in vivo response of immune cells to IFN-alpha immunotherapy.
PURPOSE: The precise molecular targets of IFN-alpha therapy in the context of malignant melanoma are unknown but seem to involve signal transducers and activators of transcription 1 signal transduction within host immune effector cells. We hypothesized that the in vitro transcriptional response of patient peripheral blood mononuclear cells (PBMC) to IFN-alpha would be similar to the in vivo response to treatment with high-dose IFN-alpha. EXPERIMENTAL DESIGN: The gene expression profiles of PBMCs and immune cell subsets treated in vitro with IFN-alpha were evaluated, as were PBMCs obtained from melanomapatients receiving adjuvant IFN-alpha. RESULTS: Twenty-seven genes were up-regulated in PBMCs from normal donors after treatment with IFN-alpha in vitro for 18 hours (>2-fold, P < 0.001). A subset of these genes (in addition to others) was significantly expressed in IFN-alpha-treated T cells, natural killer cells, and monocytes. Analysis of gene expression within PBMCs from melanomapatients (n = 13) receiving high-dose IFN-alpha-2b (20 MU/m(2) i.v.) revealed significant up-regulation (>2-fold) of 21 genes (P < 0.001). Also, the gene expression profile of in vitro IFN-alpha-stimulated patient PBMCs was similar to that of PBMCs obtained from the same patient after IFN-alpha therapy. CONCLUSIONS: This report is the first to describe the transcriptional response of T cells, natural killer cells, and monocytes to IFN-alpha and characterize the transcriptional profiles of PBMCs from melanomapatients undergoing IFN-alpha immunotherapy. In addition, it was determined that microarray analysis of patient PBMCs after in vitro stimulation with IFN-alpha may be a useful predictor of the in vivo response of immune cells to IFN-alpha immunotherapy.
Authors: Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Jason M Zimmerer; Gregory B Lesinski; Sri Vidya Kondadasula; Volodymyr I Karpa; Amy Lehman; Abhik Raychaudhury; Brian Becknell; William E Carson Journal: J Immunol Date: 2007-04-15 Impact factor: 5.422
Authors: E Maellaro; L Pacenti; B Del Bello; M A Valentini; P Mangiavacchi; C De Felice; P Rubegni; P Luzi; C Miracco Journal: Br J Dermatol Date: 2003-06 Impact factor: 9.302
Authors: Gary K Geiss; Victoria S Carter; Yupeng He; Bartlomiej K Kwieciszewski; Ted Holzman; Marcus J Korth; Catherine A Lazaro; Nelson Fausto; Roger E Bumgarner; Michael G Katze Journal: J Virol Date: 2003-06 Impact factor: 5.103
Authors: Ernest C Borden; Barbara Jacobs; Emese Hollovary; Lisa Rybicki; Paul Elson; Thomas Olencki; Pierre Triozzi Journal: J Interferon Cytokine Res Date: 2011-01-15 Impact factor: 2.607
Authors: Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan; Francesco M Marincola; Anna Di Nardo; Filamer D Kabigting; Constantin A Dasanu Journal: J Immunother Date: 2010 Jul-Aug Impact factor: 4.456
Authors: Simon J Waddell; Stephen J Popper; Kathleen H Rubins; Michael J Griffiths; Patrick O Brown; Michael Levin; David A Relman Journal: PLoS One Date: 2010-03-22 Impact factor: 3.240
Authors: Qiuzhen Liu; Sara Tomei; Maria Libera Ascierto; Valeria De Giorgi; Davide Bedognetti; Cuilian Dai; Lorenzo Uccellini; Tara Spivey; Zoltan Pos; Jaime Thomas; Jennifer Reinboth; Daniela Murtas; Qianbing Zhang; Lotfi Chouchane; Geoffrey R Weiss; Craig L Slingluff; Peter P Lee; Steven A Rosenberg; Harvey Alter; Kaitai Yao; Ena Wang; Francesco M Marincola Journal: J Clin Invest Date: 2014-04-01 Impact factor: 14.808
Authors: Yao Yuan; Siddha Kasar; Chingiz Underbayev; Daniel Vollenweider; Erica Salerno; Sergei V Kotenko; Elizabeth Raveche Journal: Mol Immunol Date: 2012-05-11 Impact factor: 4.407
Authors: Kristan D Guenterberg; Valerie P Grignol; Ene T Raig; Jason M Zimmerer; Anthony N Chan; Farriss M Blaskovits; Gregory S Young; Gerard J Nuovo; Bethany L Mundy; Gregory B Lesinski; William E Carson Journal: Mol Cancer Ther Date: 2010-01-26 Impact factor: 6.261